Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.34 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.34 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481335 | 1.00 | NFE2L2 (0.38) | NFE2L2CYP17A1CYP21A2CYP11B1RAB9A | |
| SCHEMBL1481271 | 0.81 | RELA (0.41) | NFE2L2RAB9ANPC1KMT2ATUBB4A | |
| SCHEMBL1481270 | 0.81 | RELA (0.41) | NFE2L2RAB9ANPC1KMT2ATUBB4A | |
| SCHEMBL1676373 | 0.78 | NR3C1 (0.37) | NFE2L2CYP17A1CYP3A4 | |
| SCHEMBL1676371 | 0.78 | NR3C1 (0.37) | NFE2L2CYP17A1CYP3A4 | |
| SCHEMBL1480155 | 0.77 | DHODH (0.39) | RAB9ANPC1KMT2ARXFP1TUBB4A | |
| SCHEMBL1480157 | 0.77 | DHODH (0.39) | RAB9ANPC1KMT2ARXFP1TUBB4A | |
| SCHEMBL1480478 | 0.74 | NPC1 (0.39) | NFE2L2RAB9ANPC1KMT2ATUBB4A | |
| SCHEMBL1480482 | 0.74 | NPC1 (0.39) | NFE2L2RAB9ANPC1KMT2ATUBB4A | |
| SCHEMBL1480884 | 0.74 | NPC1 (0.41) | RAB9ANPC1KMT2ARXFP1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004071447-A9 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | NFE2L2 2112/4885CYP17A1 362/4885CYP21A2 209/4885 |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | NFE2L2 2828/4885CYP17A1 170/4885CYP21A2 78/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | NFE2L2 2828/4885CYP17A1 170/4885CYP21A2 78/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | NFE2L2 2112/4885CYP17A1 362/4885CYP21A2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.